TRANSACTION RECORD

DOWNLOAD RECORD   vCard | CSV | PDF
Company Name Corridor Pharmaceuticals
Status Private & Independent
Industry Biopharmaceutical
Company Description Corridor Pharmaceuticals is a platform-based pulmonary and critical care company developing novel therapeutics forelevated arginase levels.
Mailing Address 1122 Kenilworth Dr. Suite 401
Towson, MD 21204
USA  Map
Phone 410-616-0804
Website www.corridorpharma.com
Email Click for Free Trial
Profile
Social Media
Company News
Facebook
YouTube
 
Company Management
Title Name Email Profile
     
Chief Executive Officer Strobeck, Mark
Chief Scientific Officer Suzdak, Peter
VP - Finance Shiflett, Anne
Information Release Date 10/2/2009
Transaction Type Venture Equity
Amount $10,750,000
Round Series A
Proceeds Purposes Arginetix will utilize this financing for further discovery and to continue development of its first-in-class arginase inhibitors for cardiovascular and pulmonary indications.
Transaction Investors
Quaker Partners
(Lead Investor)
Geeta Vemuri
MedImmune Ventures
(Lead Investor)
Eva Jack
Osage Partners
Red Abbey Venture Partners
Undisclosed

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.


PCI - Level1